The Growth Releaser
Modified Growth Hormone Releasing Hormone (1-29)
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone. Available in two forms — with and without Drug Affinity Complex (DAC) — it is one of the most widely prescribed peptides for growth hormone optimization. When combined with Ipamorelin, it forms the most popular growth hormone peptide combination in clinical practice.
CJC-1295 binds to GHRH receptors on the pituitary gland, stimulating natural growth hormone production while preserving the body's physiological pulsatile release pattern. The DAC modification extends its half-life for sustained effects.
Binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating synthesis and release of growth hormone.
Maintains the natural pulsatile pattern of GH release, unlike direct GH injection which creates continuous non-physiological levels.
The DAC (Drug Affinity Complex) modification extends half-life from 30 minutes to 6-8 days by binding to serum albumin.
Increases IGF-1 levels proportionally, which mediates many of growth hormone's anabolic and regenerative effects in tissues.
Promotes lean muscle growth and fat metabolism through growth hormone optimization, with research showing significant improvements in body composition over 12-week protocols.
Accelerates recovery from exercise and injury through growth hormone-mediated tissue repair, collagen synthesis, and inflammation reduction.
Growth hormone is primarily released during deep sleep. By optimizing GH pulsatility, CJC-1295 often improves sleep depth and recovery.
Counteracts the age-related decline in growth hormone production, supporting skin quality, bone density, cognitive function, and overall vitality.
CJC-1295 DAC administration resulted in sustained elevation of GH and IGF-1 levels for 6-14 days after a single injection in healthy adults, with dose-dependent responses.
Phase II clinical trial demonstrated CJC-1295 increased mean GH levels by 2-10 fold and IGF-1 by 1.5-3 fold without significant adverse effects.
Combined CJC-1295/Ipamorelin therapy showed synergistic GH release significantly greater than either peptide alone, with improved body composition markers at 12 weeks.
CJC-1295 has demonstrated a good safety profile in Phase I and Phase II clinical trials. Side effects are generally mild and related to growth hormone elevation. The non-DAC version (mod GRF 1-29) offers more precise dosing control and shorter duration of action.
Research Status
CJC-1295 has undergone Phase I and Phase II clinical trials with published results in peer-reviewed endocrinology journals. The body of evidence is strong for GH and IGF-1 elevation. Long-term clinical outcome data is still being collected.
Regulatory Note
Not FDA-approved. Available through licensed compounding pharmacies with a physician prescription. Frequently prescribed in clinical anti-aging and hormone optimization practices.